Isabel Cassetti
YOU?
Author Swipe
View article: Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice
Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice Open
Introduction: Dolutegravir plus lamivudine (DTG/3TC) dual therapy has demonstrated efficacy in HIV treatment, but access remains challenging in Latin America. Argentina approved a generic co-packaged DTG+3TC presentation to improve accessi…
View article: Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)
Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH) Open
Background Despite higher risk of poorer outcomes and potential sub-optimal vaccine effectiveness, people living with HIV (PLWH) are underrepresented in SARS-CoV-2 vaccine trials. We evaluated the safety and immunogenicity of the Ad5-nCoV …
View article: Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina
Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina Open
Background: Argentina has reported moderate to high levels of transmitted drug resistance in people living with HIV/AIDS (PLWHA), mostly to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Doravirine (DOR) has a unique resistance …
View article: Antiretroviral Therapy Adherence and Clinic Attendance Over Time Among People in Argentina Living with HIV and Lost to Care
Antiretroviral Therapy Adherence and Clinic Attendance Over Time Among People in Argentina Living with HIV and Lost to Care Open
Background Although Argentina provides access to no cost HIV care, treatment adherence and retention in care remain suboptimal. This study aimed to explore factors associated with self-reported adherence and appointment attendance over tim…
View article: Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort
Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort Open
Introduction. Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited. Material and methods. We conducted an observational re…
View article: Unity is strength: creation and future actions for a consortium for HIV cure research in Latin America and the Caribbean ‘Lac-Cura’
Unity is strength: creation and future actions for a consortium for HIV cure research in Latin America and the Caribbean ‘Lac-Cura’ Open
The development of effective HIV cure strategies is crucial. However, most research in this area has been concentrated in high-income countries, underscoring the need to expand efforts to regions like Latin America and the Caribbean (LAC),…
View article: 365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment Open
Background Fostemsavir (FTR), the prodrug of the first-in-class attachment inhibitor temsavir, is indicated in combination with other antiretrovirals (ARVs) for heavily-treatment experienced (HTE) people with multidrug-resistant HIV-1 unab…
View article: Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV
Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV Open
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens. People living with …
View article: Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials Open
Importance The COVID-19 pandemic has caused millions of infections and deaths and resulted in unprecedented international public health social and economic crises. As SARS-CoV-2 spread across the globe and its impact became evident, the de…
View article: Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV
Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV Open
Objective: This study describes adverse events following immunization (AEFIs) and the development of SARS-COV-2 antibodies after Sputnik V, AstraZeneca, and Sinopharm COVID-19 vaccination in people with HIV (PWH). Methods: In total, 595 ad…
View article: A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care
A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care Open
National Institutes of Health.
View article: Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 Open
Objectives: The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. Design: BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and opt…
View article: Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection
Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection Open
Background Possible human immunodeficiency virus (HIV)-1 clearance has rarely been reported. In this study, we describe a unique case of an HIV-positive, combination antiretroviral therapy (cART)-experienced woman with prior acquired immun…
View article: Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina Open
Objective. There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and v…
View article: Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey. Open
Integrase resistance test was prescribed almost exclusively in heavily pretrated raltegravir-exposed patients. The three main mutational pathways were described, with a predominance of N155H. Despite almost null susceptibility and extensiv…
View article: Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care
Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care Open
This study evaluated the reasons for not taking antiretroviral treatment (ART) among women of reproductive age who are disengaged from HIV care (have missed pharmacy pickups and physician visits), with the goal of identifying strategies fo…
View article: 1900. Low Prevalence of Protective Antibodies to Measles Among Young Adults in Argentina
1900. Low Prevalence of Protective Antibodies to Measles Among Young Adults in Argentina Open
BACKGROUND: In the last years, there has been an increase in incidence of cases of measles in high and middle-income countries. In Argentina, measles elimination was achieved in 2000, with no circulation of measles virus since then; vaccin…
View article: Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial
Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial Open
ClinicalTrials.gov, ID: NCT02846350 . Registered on 1 July 2016.
View article: HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico Open
The development of potent interferon-free regimens of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection has moved at a remarkable pace. Highly effective, extremely well-tolerated regimens are now availa…
View article: Implementation and uptake of the Conexiones y Opciones en la Argentina intervention: feasibility and acceptability
Implementation and uptake of the Conexiones y Opciones en la Argentina intervention: feasibility and acceptability Open
Challenging HIV-infected patients, those neither adherent nor actively engaged in care, represent an important opportunity for intervention if the HIV epidemic is to be contained. This pilot study assessed the feasibility and acceptability…
View article: O113: Barriers to care and reproductive choices in Latin American HIV+ women: a subanalysis of the ELLA Study
O113: Barriers to care and reproductive choices in Latin American HIV+ women: a subanalysis of the ELLA Study Open
Antiretroviral therapies have proved life-saving in HIV infection, dramatically reducing morbidity and mortality.With longer survival, morbidities and mortalities in HIV infection are increasingly similar to the morbidities and mortalities…